Exhibit 10.2


 


EXECUTION VERSION


 





 



 


EXCHANGE AGREEMENT


 


by and among


 


Protalix BioTherapeutics, Inc.


 


and


 


the Parties Signatory Hereto 


 


Dated as of July 24, 2017


 





 



 




     

     


    

 


EXCHANGE AGREEMENT dated as of July 24, 2017
(this “Agreement”), by and among Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”),
and the parties signatory hereto (each, a “Purchaser,” and collectively, the “Purchasers”).


 


BACKGROUND


 


As of the date hereof, each Purchaser owns
and holds an aggregate principal amount of the Company’s 4.50% Convertible Senior Notes due 2018 (the “Existing
Notes”) as identified opposite such Purchaser’s name on Schedule I hereto. The Existing Notes have the covenants
and terms set forth in the Indenture dated as of September 18, 2013 (the “Existing Indenture”), between the
Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”). All capitalized terms
used herein that are not otherwise defined shall have the meanings ascribed to them in the Existing Indenture.


 


The Company and the Purchasers desire to exchange
(the “Exchange”) Existing Notes for (a) newly issued 4.50% Senior Convertible Notes due 2022 (the “Exchange
Notes”); and (b) cash in the amount set forth on Schedule I hereto opposite such Purchaser’s name (the “Cash
Consideration”) and (c) cash in the amount of accrued and unpaid interest on such Existing Notes through, but excluding,
the Closing Date (as defined below), in a transaction exempt from registration under the Securities Act of 1933, as amended (the
“Securities Act”), pursuant to the provisions of Section 3(a)(9) thereof.


 


In consideration of the mutual covenants and
agreements contained in this Agreement, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally
bound, the Company and the Purchasers, severally but not jointly, hereby agree as follows:


 


ARTICLE
I



EXCHANGE


 


Section 1.1           Exchange.
The Company agrees to issue to each Purchaser that principal amount of Exchange Notes, and pay to such Purchaser that amount of
cash in U.S. dollars representing the Cash Consideration and any accrued and unpaid interest on the Existing Notes of such Purchaser,
set forth on Schedule I hereto opposite such Purchaser’s name, in exchange for Existing Notes of such Purchaser having
the aggregate principal amount set forth on Schedule I hereto opposite such Purchaser’s name, and such Purchaser,
severally and not jointly, agrees to exchange all such Existing Notes for such Exchange Notes and cash. In addition to the Cash
Consideration, for each $1,000 principal amount of Existing Notes exchanged by a Purchaser, such Purchaser will receive (a) $950
aggregate principal amount of Exchange Notes (which, based on the total principal amount of Exchange Notes issuable to such Person,
will be rounded up to the nearest $1,000 in principal amount, if applicable), and (b) $16.25 in cash for accrued and unpaid interest
on such Exchange Notes (the Cash Consideration together with the consideration referenced in the foregoing clauses (a) and (b),
the “Exchange Consideration”).


 




    	 	1	 



     


    

 


Section 1.2           Exchange
Procedures.


 


(a)             The
closing of the Exchange (the “Closing”) will be held on the date of this Agreement (the “Closing Date”).
No later than 10:00 a.m., New York City time, on the Closing Date, each Purchaser shall cause its custodian through which such
Purchaser holds its Existing Notes to post a DWAC request to the Trustee (i) to effect the transfer of the Existing Notes in accordance
with the procedures of The Depository Trust Company (“DTC”), into a book-entry account established by or on
behalf of the Company, and to use commercially reasonable efforts to ensure that the Trustee receives an agent’s message
from DTC confirming the book-entry transfer of the Existing Notes, and (ii) for free receipt to the Trustee for the aggregate principal
amount of Exchange Notes opposite such Purchaser’s name on Schedule I hereto. The delivery of the Existing Notes by
each Purchaser will be complete upon receipt by the Trustee on the Closing Date of an agent’s message, book-entry confirmation
from DTC and any other required documents.


 


(b)             On
the Closing Date, the Company, or Trustee at the Company’s direction, will (i) cause the Exchange Notes to be credited to
the DTC accounts identified by such Purchaser (as specified on its signature page hereof) against delivery of the Existing Notes,
as set forth on Schedule I hereto, (ii) cause the payment of Cash Consideration as set forth on Schedule I hereto,
by wire transfer of immediately available funds to the accounts previously provided in writing by such Purchaser and (iii) cause
the payment of cash for accrued interest owed on the Existing Notes through, but excluding, the Closing Date, as set forth on Schedule
I hereto, by wire transfer of immediately available funds to the accounts previously provided in writing by such Purchaser.


 


(c)             
For the avoidance of doubt, the Purchasers shall cease to own any Existing Notes as of the crediting of the Exchange Notes to the
DTC accounts identified by the Purchasers, the payment of the Cash Consideration, and the payment of cash for accrued interest
on the Existing Notes by wire transfer as provided in the immediately preceding sentence, and the Company shall be entitled to
instruct the appropriate parties to immediately thereafter cancel the Existing Notes on the books and records of the Company.


 


ARTICLE
II


 


REPRESENTATIONS AND WARRANTIES OF THE COMPANY


 


The Company represents and warrants to, and
agrees with, each Purchaser, as of the Closing Date, as follows:


 


Section 2.1           Existence
and Power. The Company is a duly organized and validly existing corporation in good standing under the laws of the State of
Delaware and has the corporate power and authority to own its properties and conduct its business as currently conducted. The Company’s
subsidiaries, Protalix Ltd. and Protalix B.V., are duly organized and validly existing in good standing under the laws of Israel
and the Netherlands, respectively, and have the organizational power and authority to hold their respective properties and conduct
their businesses as currently conducted. The Company does not have any “significant subsidiary” as defined in Rule
1-02 of Regulation S-X that is not listed above.


 




    	 	2	 



     


    

 


Section 2.2           Authorization
and Enforceability. The execution, delivery and performance of this Agreement and each other document, instrument or agreement
executed and delivered by the Company in connection with the transactions contemplated hereby has been duly authorized by all necessary
action on the part of the Company, and this Agreement and each other document, instrument or agreement executed and delivered by
the Company in connection with the transactions contemplated hereby, when duly executed and delivered by the parties hereto and
thereto, will be the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its
terms (subject, as to the enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium or other laws
affecting creditors’ rights generally from time to time in effect and to general principles of equity).


 


Section 2.3           Capitalization.
All issued and outstanding shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”)
have been duly authorized and validly issued and are fully paid and nonassessable, and none of the outstanding shares of Common
Stock were issued in violation of any preemptive or similar rights of any securityholder of the Company. The issued and outstanding
shares of capital stock or other equity interests of each of the Company’s subsidiaries have been duly authorized and validly
issued, are fully paid and nonassessable and are owned by the Company free and clear of any security interests, liens, encumbrances,
equities or claims of any third party, except as described in the Reports (as defined below).


 


Section 2.4           Valid
Issuance of Exchange Notes; Enforceability of Notes and Indenture. The Exchange Notes have been duly executed by the Company
and, when authenticated by the Trustee in accordance with the indenture by and between the Company and the other parties identified
therein (the “Indenture”), and delivered and paid for as provided herein, will be the legal, valid and binding
obligations of the Company, enforceable against the Company in accordance with their terms and entitled to the benefits of the
Indenture (subject, as to the enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium or other
laws affecting creditors’ rights generally from time to time in effect and to general principles of equity); the number of
shares of Common Stock initially issuable upon conversion of the Exchange Notes at the initial Conversion Rate of 1,176.4706, will
be duly authorized and, when issued upon conversion of the Exchange Notes in accordance with the Indenture, will be validly issued,
fully paid and nonassessable; the maximum number of shares of Common Stock initially issuable upon conversion of the Exchange Notes
(including the maximum number of additional shares that may be issued in connection with a “Make-Whole Adjustment Event,”
assuming all conversions are settled solely in shares of Common Stock (the “Maximum Number of Shares”) has been
duly authorized and, when issued upon conversion of the Exchange Notes in accordance with the Indenture, will be validly issued,
fully paid and nonassessable; the Indenture has been duly authorized and, assuming due authorization, execution and delivery thereof
by the Trustee, when executed and delivered by the Company, will constitute a legal, valid, binding instrument enforceable against
the Company in accordance with its terms (subject, as to the enforcement of remedies, to applicable bankruptcy, reorganization,
insolvency, moratorium or other laws affecting creditors’ rights generally from time to time in effect and to general principles
of equity); the Board of Directors of the Company has duly and validly adopted resolutions reserving a number of shares of Common
Stock for issuance upon conversion of the Exchange Notes equal to the Maximum Number of Shares; and such shares of Common Stock
are not subject to any preemptive or similar right.


 




    	 	3	 



     


    

 


Section 2.5           Non-Contravention/No
Consents. The execution and delivery of this Agreement, the Indenture and the Notes, the consummation of the transactions herein
and therein contemplated, and the fulfillment of the terms hereof and thereof, will not conflict with, result in a breach or violation
or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant
to, (a) the charter or by-laws or comparable constituting documents of the Company or any of its subsidiaries; (b) the terms of
any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition,
covenant or instrument to which the Company or any of its subsidiaries is a party or bound or to which its or their property is
subject; or (c) any statute, law, rule, regulation, judgment, order or decree of any court, regulatory body, administrative agency,
governmental body, arbitrator or other authority having jurisdiction over the Company or any of its subsidiaries or any of its
or their properties, except, in the cases of clauses (b) and (c), as would not, singly or in the aggregate, have a material adverse
effect on the condition (financial or otherwise), prospects, earnings, business or properties of the Company and its subsidiaries,
taken as a whole, whether or not arising from transactions in the ordinary course of business (a “Material Adverse Effect”).
Subject to the Aggregate Share Cap (as defined in the Indenture), no stockholder approval is required under the rules of the NYSE
MKT LLC (“NYSE MKT”) in connection with the issuance of the Exchange Notes.


 


Section 2.6           SEC
Reports. The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, as amended, and all other
reports filed by the Company with the Securities and Exchange Commission (the “SEC”) pursuant to Section 13(a),
Section 14 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since December
31, 2016 and prior to the date hereof (collectively, the “Reports”), when they were filed with the SEC, complied
as to form in all material respects with the applicable requirements under the Exchange Act, and did not, when such Reports were
so filed, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Prior to
the Closing, there shall not have occurred a Material Adverse Effect or any development involving a prospective Material Adverse
Effect in the general affairs, business, properties, management, financial condition or results of operations of the Company from
that set forth in the Reports.


 




    	 	4	 



     


    

 


Section 2.7           No
Brokers. Neither the Company nor any of its subsidiaries nor any of their respective officers, directors, employees or agents
has incurred any liability for any commissions or other remuneration in connection with the Exchange.


 


Section 2.8           Section
3(a)(9) Exemption. It is not necessary in connection with the Exchange, in the manner contemplated herein, to register the
issuance of the Exchange Notes under the Securities Act in reliance on the exemption from registration set forth under Section
3(a)(9) of the Securities Act. Neither the Company nor anyone acting on the Company’s behalf has received any commission
or remuneration directly or indirectly in connection with or in order to solicit or facilitate the Exchange.


 


Section 2.9           No
Restrictions on Sale. Assuming the accuracy of the Purchasers’ representations and warranties hereunder, the Exchange
Notes will, as of the Closing Date, be free of any restrictive legend or other restrictions on resale by the Company and will be
issued in book-entry form, represented by permanent global certificates deposited with, or on behalf of, The Depositary Trust Company
represented by the unrestricted CUSIP assigned to the Company’s Common Stock.


 


Section 2.10         Properties.
Each of the Company and its subsidiaries owns or leases all such properties as are reasonably necessary to the conduct of its operations
as presently conducted.


 


Section 2.11         Intellectual
Property. The Company and its subsidiaries own, possess, license or otherwise have adequate rights to use, on reasonable terms,
all patents, trademarks, service marks, trade names, copyrights and copyrightable works, licenses, inventions, trade secrets, technology,
know-how (whether or not patentable) and other intellectual property or proprietary rights (including all registrations and applications
for registration of, and all goodwill associated with the foregoing) (collectively, the “Intellectual Property”)
necessary for the conduct of the Company’s business as now conducted. None of the events, singly or in the aggregate, have
a Material Adverse Effect: (a) there are no rights of third parties to any such Intellectual Property except as disclosed
in the Reports; (b) to the Company’s knowledge, there is no material infringement by third parties of any such Intellectual
Property; (c) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others
challenging the Company’s rights in or to any such Intellectual Property, and the Company is unaware of any facts which would
form a reasonable basis for any such claim; (d) there is no pending or, to the Company’s knowledge, threatened action, suit,
proceeding or claim by others challenging the validity or scope of any such Intellectual Property, and the Company is unaware of
any facts which would form a reasonable basis for any such claim; (e) there is no pending or, to the Company’s knowledge,
threatened action, suit, proceeding or claim by others that the Company infringes or otherwise violates any Intellectual Property
or other proprietary rights of others, and the Company is unaware of any other fact which would form a reasonable basis for any
such claim; (f) there is no U.S. patent or published U.S. patent application which contains claims that have (or may have) priority
over or dominate (or may dominate) any Intellectual Property owned by or licensed to the Company or that interferes with the issued
or pending claims of any such Intellectual Property; and (g) there is no prior art of which the Company is aware that may
render any U.S. patent held by the Company invalid or any U.S. patent application held by the Company unpatentable which has not
been disclosed to the U.S. Patent and Trademark Office.


 




    	 	5	 



     


    

 


ARTICLE
III


 


REPRESENTATIONS
AND WARRANTIES OF THE PURCHASERS


 


Each Purchaser, severally but not jointly,
represents and warrants to, and agrees with, the Company, as of the Closing Date, as follows:


 


Section 3.1           Existence
and Power. Such Purchaser is duly organized and validly existing under the laws of the jurisdiction of its organization and
has all requisite power and authority to enter into and perform its obligations under this Agreement.


 


Section 3.2           Authorization.
The execution, delivery and performance of this Agreement and each other document, instrument or agreement executed and delivered
by such Purchaser in connection with the transactions contemplated hereby has been duly authorized by all necessary action on the
part of such Purchaser, and this Agreement and each other document, instrument or agreement executed and delivered by such Purchaser
in connection with the transactions contemplated hereby, when duly executed and delivered by the parties hereto and thereto, is
a valid and binding obligation of such Purchaser, enforceable against it in accordance with its terms (subject, as to the enforcement
of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium or other laws affecting creditors’ rights generally
from time to time in effect and to general principles of equity). Such Purchaser has the full right, power, legal capacity and
authority to sell and transfer the Existing Notes and to enter into and perform its obligations under this Agreement.


 


Section 3.3           Governmental
Authorization. As of the date hereof, no permit, authorization, consent or approval of or by, or any notification of or filing
with, any Person (governmental or private) is required to be obtained or made by such Purchaser in connection with the execution,
delivery and performance by it of this Agreement, the consummation by it of the transactions contemplated hereby or thereby, or
the issuance or delivery to it by the Company of the Exchange Notes, other than a filing on a Schedule 13G or 13D (or 13G/A or
13D/A), if applicable.


 


Section 3.4           Non-Contravention/No
Consents. The execution, delivery and performance of this Agreement will not conflict with, violate or result in a breach of
any provision of, or constitute a default under, or result in the termination of or accelerate the performance required by (a)
any provision of the organizational documents of such Purchaser, (b) any mortgage, note, indenture, deed of trust, loan agreement
or other agreement or instrument to which such Purchaser is a party or by which such Purchaser is bound or to which any of the
property or assets of such Purchaser is subject; or (c) any law, statute, rule, regulation, judgment, order, writ or decree of
any arbitrator, court, governmental body, regulatory body, or administrative agency having jurisdiction over such Purchaser or
any of its properties or assets, other than any such conflict, violation, breach, default, termination and acceleration under clauses
(b) and (c) that would not reasonably be expected to materially adversely impact the ability of such Purchaser to consummate the
transactions contemplated hereby.


 




    	 	6	 



     


    

 


Section 3.5           No
Brokers. Such Purchaser has not employed any broker or finder in connection with the transactions contemplated by this Agreement.


 


Section 3.6           Purchaser
Status. Such Purchaser acknowledges that (a) it meets the definition of “qualified institutional buyers” as defined
in Rule 144A(a)(1) under the Securities Act; and (b) is not an entity formed for the sole purpose of acquiring the Notes. Such
Purchaser is not an “affiliate” of the Company within the meaning of Rule 144 under the Securities Act.


 


Section 3.7           Company
Information. Such Purchaser represents that in connection with this Agreement and the Exchange contemplated hereby it is relying
solely on the information relating to the Company’s business, finances and operations contained in the Reports and further
acknowledges that the Company makes no representation or warranty with respect to any matters relating to the Company, its business,
financial condition, results of operations, prospects or otherwise, except to the extent expressly provided in Article II hereof.


 


Section 3.8           
Undertaking. Each Purchaser undertakes (a) to observe all the requirements of the Israeli Encouragement of Research, Development
and Technological Innovation in Industry Law, 5744-1984 (the “Innovation Law”) and the provisions of the applicable
regulations, rules, procedures and benefit plans, as applied to Protalix Ltd. and as directed by the research committee of the
Israeli National Authority for Technological Innovation (the "Research Committee" and the “IIA”,
respectively), in particular those requirements relating to the prohibitions on the transfer of know-how and/or production rights;
and (b) as a stockholder of the Company, to make all reasonable efforts to cause Protalix Ltd. to observe strictly all the requirements
of the Innovation Law and the provisions of the applicable regulations, rules, procedures and benefit plans, as applied to Protalix
Ltd. and as directed by the Research Committee, in particular those requirements relating to the prohibitions on the transfer of
know-how and/or production rights.


 


Section 3.9           Risks
of Investment. Such Purchaser fully understands the risks relating to an investment in the Exchange Notes. Such Purchaser is
able to bear the economic risk of holding the Exchange Notes for an indefinite period (including total loss of its investment),
and has sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and
risk of its investment.


 




    	 	7	 



     


    

 


Section 3.10         No
Encumbrances. Such Purchaser is the sole and exclusive holder of the Existing Notes free and clear of all liens, pledges, hypothecations,
claims, restrictions or encumbrances, and no other person, firm or corporation has any interest whatsoever in the Existing Notes
(other than pledges or security interests that such Purchaser may have created in favor of a prime broker under and in accordance
with its prime brokerage agreement with such broker). The Exchange provided for herein will vest in the Company valid and absolute
title to the Existing Notes, free and clear of any and all encumbrances, liens, pledges, hypothecations, restrictions, claims,
options, agreements and conditions.


 


Section 3.11         Section
3(a)(9) Exemption. Such Purchaser acknowledges that in connection with the Exchange, in the manner contemplated herein, the
Company intends to rely on the exemption from registration set forth under Section 3(a)(9) of the Securities Act. Such Purchaser
knows of no reason why such exemption is not available.


 


Section 3.12         Investment
Purpose. Such Purchaser is acquiring the Exchange Notes solely for its own account for investment purposes and not with a view
to, or for offer or sale in connection with, any distribution thereof. Such Purchaser acknowledges that the offer and sale of the
Exchange Notes is not registered under the Securities Act, or any state securities laws, and that the Exchange Notes may not be
transferred or sold except pursuant to the registration provisions of the Securities Act or pursuant to an applicable exemption
therefrom and subject to state securities laws and regulations, as applicable.


 


Section 3.13         No
View to Effecting Exchange. Such Purchaser did not acquire the Existing Notes with a view to effecting the Exchange.


 


Section 3.14         Holding
Period. Such Purchaser or, to the best of such Purchaser’s knowledge, any person who is not an “affiliate”
of the Company within the meaning of Rule 144 under the Securities Act has beneficially owned the Existing Notes being exchanged
by such Purchaser in the Exchange for a period of at least one year within the meaning of Rule 144(d) under the Securities Act.


 


Section 3.15         Reliance.
Such Purchaser acknowledges that the Company will rely upon the truth and accuracy of the foregoing representations and warranties.


 


ARTICLE
IV


 


CLOSING
CONDITIONS


 


Section 4.1           Conditions
to the Company’s Obligations. The Company’s obligation to complete the Exchange at the Closing shall be subject
to the following conditions, any one or more of which may be waived by the Company:


  


(a)              receipt
by the Company of the Existing Notes being exchanged hereunder and satisfaction by each Purchaser of all of its obligations contemplated
by this Agreement in connection with the Exchange;


 




    	 	8	 



     


    

 


(b)             completion
of the purchase of $10 million aggregate principal amount of the Company’s 7.50% Senior Secured Convertible Notes due 2021
pursuant to the Note Purchase Agreement dated the date hereof by and among the Company and the parties identified therein (the
“Concurrent Private Placement of 7.50% Notes”);


 


(c)              receipt
by each Purchaser of a duly executed Letter of Undertaking to the IIA, in the form attached hereto as Exhibit D, to be held
in trust by the Company and delivered to the IIA only upon and subject to such Purchaser’s (and its affiliates) holdings
in the Company equal to or exceeds 5% of the Company’s share capital on a fully diluted basis;


 


(d)             the
accuracy of the representations and warranties made by the Purchasers in this Agreement; and


 


(e)              no
injunction, restraining order, action or order of any nature by a governmental or regulatory authority shall have been issued,
taken or made and no action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or
issued by any federal, state or foreign governmental or regulatory authority of competent jurisdiction that would, as of the Closing
Date, prevent or materially interfere with the consummation of the transactions contemplated by this Agreement.


 


Section 4.2           Conditions
to the Purchasers’ Obligations. Each Purchaser’s obligation to complete the Exchange at the Closing shall be subject
to the following conditions, any one or more of which may be waived by such Purchaser:


 


(a)              completion
of the Concurrent Private Placement of 7.50% Notes;


 


(b)              the
Common Stock shall continue to be listed on the NYSE MKT as of the Closing Date; there shall have been no suspensions in the trading
of the Common Stock as of the Closing Date; and the listing of additional shares notification form with respect to the Maximum
Number of Shares shall have been submitted to NYSE MKT and NYSE MKT shall have confirmed that it has no objection to such notification;


 


(c)              no
injunction, restraining order, action or order of any nature by a governmental or regulatory authority shall have been issued,
taken or made and no action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or
issued by any federal, state or foreign governmental or regulatory authority of competent jurisdiction that would, as of the Closing
Date, prevent or materially interfere with the consummation of the transactions contemplated by this Agreement;


 


(d)              receipt
by such Purchaser of fully executed copies of the Indenture and the Exchange Notes;


 


(e)              the
delivery to such Purchaser by U.S. counsel to the Company of a legal opinion substantially similar in substance to the form of
opinion attached as Exhibit A;


 


(f)              receipt
by such Purchaser of a certificate executed by the chief executive officer and the chief financial officer of the Company, dated
as of the Closing Date, in substantially the form of certificate attached as Exhibit B;


 




    	 	9	 



     


    

 


(g)              receipt
by such Purchaser of a certificate of the Secretary of the Company, dated as of the Closing Date, in substantially the form of
certificate attached as Exhibit C;


 


(i)          certifying
the resolutions adopted by the Board of Directors of the Company approving the Exchange and the reservation and issuance of the
shares of Common Stock potentially issuable upon the conversion of the Exchange Notes;


 


(ii)         certifying
the current versions of the Certificate of Incorporation and the Bylaws of the Company; and


 


(iii)        certifying
as to the signatures and authority of the persons signing this Agreement and related documents on behalf of the Company;


 


(h)              receipt
by such Purchaser of a certificate of good standing for the Company for its jurisdiction of incorporation;


 


ARTICLE
V


 


MISCELLANEOUS


 


Section 5.1           Definitions.


 


(a)             As
used herein, the following terms have the following meanings:


 


“Business Day”
means any day other than a Saturday, a Sunday or a day on which the Federal Reserve Bank of New York, Wilmington, Delaware or the
place of payment is authorized or required by law or executive order to close or be closed.


 


“Person” or
“person” shall mean an individual, corporation, association, partnership, trust, joint venture, business trust
or unincorporated organization, or a government or any agency or political subdivision thereof.


 


Section 5.2           Notices.
All notices and other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed
to have been given if delivered personally or by facsimile or three Business Days after having been sent by certified mail, return
receipt requested, postage prepaid, to the parties to this Agreement at the following address or to such other address either party
to this Agreement shall specify by notice to the other party:


 


 (i)             If to the Company:




Protalix BioTherapeutics, Inc.


2 Snunit Street, Science Park, POB
455,


Carmiel 20100, Israel


Attention: Moshe Manor, President
and Chief Executive Officer.


Facsimile: 972-4-902-8102


E-mail: moshe.manor@protalix.com


 




    	 	10	 



     


    

 


with a copy to (which shall not
constitute notice):


 


Morrison & Foerster LLP


250 West 55th Street


New York, New York 10019


Attention: Anna T. Pinedo


Facismile: 1-212-468-7900


E-mail: apinedo@mofo.com


 


(ii)              if
to such Purchaser, at its address as set forth on the signature page to this Agreement or such other address as may have been previously
furnished to the Company in writing.


 


Section 5.3           Further
Assurances. Each party hereto shall do and perform or cause to be done and performed all further acts and shall execute and
deliver all other agreements, certificates, instruments and documents as the other party hereto reasonably may request in order
to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.


 


Section 5.4           Amendments
and Waivers.


 


(a)              Any provision of this Agreement
may be amended or waived if, but only if, such amendment or waiver is in writing and is duly executed and delivered by the Company
and Purchasers.


 


(b)              No
failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall
any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power
or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided
by law.


 


Section 5.5           Fees
and Expenses. Each party hereto shall pay all of its own fees and expenses (including attorneys’ fees) incurred in connection
with this Agreement and the transactions contemplated hereby.


 


Section 5.6           Successors
and Assigns. The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns, provided that neither party may assign, delegate or otherwise transfer any of its rights or
obligations under this Agreement without the prior written consent of the non-assigning party hereto. Notwithstanding the previous
sentence, each Purchaser may assign its rights and obligations under this Agreement to one or more of such Purchaser’s wholly
owned subsidiaries that agrees in writing with the Company to be bound by the terms and provisions of this Agreement to the same
extent as such Purchaser, but no such assignment shall relieve such Purchaser of its obligations hereunder.


 




    	 	11	 



     


    

 


Section 5.7           Governing
Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.


 


Section 5.8           Jurisdiction;
Waiver of Jury Trial.


 


(a)              The
parties hereto agree that any suit, action or proceeding seeking to enforce any provisions of, or based on any matter arising out
of or in connection with, this Agreement and the transactions contemplated hereby may only be brought in the United States District
Court for the Southern District of New York or any New York State court sitting in the Borough of Manhattan in New York City, and
each of the parties hereby consents to the jurisdiction of such courts (and of the corresponding appellate courts) in any such
suit, action or proceeding and irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter
have to the venue of any such suit, action or proceeding in any of those courts or that any such suit, action or proceeding which
is brought in any of those courts has been brought in an inconvenient forum. Process in any such suit, action or proceeding may
be served on any party anywhere in the world, whether within or without the jurisdiction of any such court.


 


(b)              THE
PARTIES HERETO HEREBY IRREVOCABLY WAIVE ANY AND ALL RIGHTS TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO
THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.         


 


 Section 5.9           Entire
Agreement. This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter of
this Agreement and supersedes all prior agreements and understandings, both oral and written, between the parties hereto with respect
to the subject matter of this Agreement.


 


 Section 5.10         Effect
of Headings. The Article and Section headings herein are for convenience only and shall not affect the construction hereof.


 


 Section 5.11         Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be deemed to
be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision were so excluded and
shall be enforced in accordance with its terms to the maximum extent permitted by law.


 


 Section 5.12         Public
Announcements. Subject to each party’s disclosure obligations imposed by law, each of the parties hereto agree that the
terms of this Agreement shall not be disclosed or otherwise made available to the public and that copies of this Agreement shall
not be publicly filed or otherwise made available to the public. 


 


Section 5.13         Counterparts;
Third Party Beneficiaries. This Agreement may be signed in any number of counterparts, each of which shall be an original,
with the same effect as if the signatures were upon the same instrument. No provision of this Agreement shall confer upon any Person
other than the parties hereto any rights or remedies hereunder.


 




    	 	12	 



     


    

 


Section 5.14         Withholding.
On the date hereof (and at any other time or times prescribed by applicable law or as reasonably requested by the Company), each
Purchaser shall deliver to the Company a properly completed and duly executed IRS Form W-9 , Form W-8BEN, W-8BEN-E or other appropriate
Form W-8 (or successor form), together with any other information necessary in order to establish an exemption from, or a reduced
rate of, U.S. federal income tax withholding, and except to the extent that an exemption or reduction is properly established,
all payments to be made by the Company in respect of the Exchange Notes shall be made net of deduction or withholding for or on
account of taxes as required by applicable law. Each Purchaser shall promptly notify the Company if at any time such previously
delivered IRS forms or information are no longer correct or valid.


 


Section 5.15         Isolated
Recapitalization. The Company and the Purchasers intend that, for U.S. federal income tax purposes, the Exchange qualify as
a plan of reorganization and as an isolated transaction that is a recapitalization within the meaning of Section 368(a)(1)(E) of
the Code.


 


Section 5.16         Other
Transactions. The Company represents to each Purchaser that the Company has not (a) agreed or entered into any arrangements
with any holder of Existing Notes to exchange such Existing Notes for other securities or other consideration, other than pursuant
to the Exchange and this Agreement; or (b) agreed or entered into any arrangements with any Purchaser to provide for the exchange
of such Purchaser’s Existing Notes on terms that differ from the terms set forth in this Agreement; provided, however,
that nothing in this Section 5.16 will affect the Company’s ability to effect any future exchange of any of its securities
on terms that may differ from the terms set forth in this Agreement.


 


Section 5.17         Miscellaneous.
For the avoidance of doubt, each representation, warranty, obligation and covenant of each Purchaser herein relates solely to that
Purchaser and no Purchaser shall be liable for the inaccuracy of any representation or warranty or any breach of any obligation
or covenant of another Purchaser hereunder.


 


[Signature Page Follows]


 




    	 	13	 



     


    

 


IN WITNESS WHEREOF, the parties hereto
have caused this Agreement to be duly executed by their respective authorized officers as of the day and year first above written.


 


	 	PROTALIX BIOTHERAPEUTICS, INC.
	 	 
	 	By:	/s/ Yossi Maimon
	 	Name:	Yossi Maimon
	 	Title:	Chief Financial Officer